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Excretory mechanisms Íor cationic drugs
Summary
In this thesis some molecular aspects of transmembrane
transport of drugs are studied, as mediated by P-glycoprotein and
other related transport proteins. These membrane proteins are
present in liver, kidneys and intestine and it is hypothesized that
they are involved in the elimination of cationic drugs from the body
via bile, urine and small intestinal contents (faeces).
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Summary
The literature that describes the mechanisms of organic cation transport in
the liver is summarized in the introductory chapter, 2. Tt.e current knowledge
about carrier-mediated hepatic uptake processes of cationic compounds as well as
the studies on the identification of various secretory processes involved in the
biliary secretion of organic cations is reviewed. For example, the molecular
identification and cloning of a member of these transport proteins is described.
In chnpter 3 the potential influence of Protein Kinase C (PKC)-mediated
phosphorylation of transport proteins on organic cation secretion into bile is
described. It was found that activating agents such as phorbol 12-myristate 13-
acetate (PMA) and vasopressin can largely stimulate the biliary excretion rate of
TBUMA, whereas the PKC antagonist staurosporin inhibited the TBuMA biliary
excretion rate. cAMP-mediated phosphorylation did not seem to play a
significant role in the biliary excretion of organic cations. It is speculated that an
ATP-dependent transport protein, localized at the hepatocyte canalicular plasma
membrane domain, is involved in the cationic drug secretion into bile. Apart from
P-glycoprotein (P-gp) various other ATP-dependent transporters are potential
candidates.
The molecular mechanism of cationic drug transport across the canalicular
membrane was further studied in canalicular membrane vesicle enriched liver
plasma membrane preparation (cLPM) (chapter 4). This chapter describes the
potential role of a organic cation: proton exchanger that can mediate the transport
of TBuMA in cLPM vesicles. The observed transport was depended on an
outwardly directed pH-gradient and could be cis-inhibited by several cationic
model drugs such as decynium22 and vecuronium. Addition of ATP did not
stimulate TBuMA uptake into cLPM vesicles. [3H]-TBuMA uptake into cLPM
vesicles was trans-stimulated upon preloading vesicles with non-radioactive
labeled TBuMA. This indicated that this organic cation antiporter differs from the
primary active P-glycoprotein and can function bidirectionally.
Organic cation transport in the intact rat liver was extensively investigated and
described in chapter 5. This chapter deals with the potential interaction during
membrane transport at the bile canalicular level during co-administration oÍ
cationic drugs. A significant correlation between the size reduction of biliary
output of the investigated model compounds doxorubicin, rocuronium and
TBuMA, and the lipophilicity of a series of lipophilic P-gp substrates was found.
This indicates that the relative affinity of the cationic drug for the supposed
transport protein, is influenced by the hydrophobic interaction with the
particular transporters. Alternatively, this physicochemical feature may influence
the partitioning of cationic drugs into the lipid-phase of the membrane, a process
that may be involved in the association of substrates to drug-binding site(s) in the
potential transport protein.
Since an excess of the competing agents did only produce a partial inhibition of
cationic drug secretion into bile and since transport inhibition was not mutual in
some cases/ we postulated that besides P-glycoprotein other carriers are probably
involved in drug secretion. One example could be the organic cation: proton
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Excretory mechanisms Íor cationic drugs
and/ or accessibility to the transporters of the model drugs and the various
inhibitors used could play a role.
A mdrla P-gp deficient mouse model was generated to further substantiate the
contribution of drug transporting P-gp to elimination of iv administered cationic
drugs from the body (see chapter 6). Absence of the mdrla P-gp resulted in a
significant reduction of the biliary and intestinal clearance of organic cations
compared to the wild-type. This implies that P-gp is likely to be involved both in
the hepatobiliary as well as in the intestinal secretion of cationic compounds like
TBuMA, APM and vecuronium in mice. Urinary clearance of small typel cationic
compounds seemed also to be affected by the absence of the mdrLa P-gp,
although for TBuMA the difference between wild-type and mdrLa (-/-) mice did
not reach statistical significance (p=O.Og). We hypothesized that the residual
biliary output of cationic compounds in mdrla P-gp deficient mice is mediated by
mdrlb P-gp and/or the functionally described organic cation: proton antiporter
that was earlier mentioned.
The role of mdrL-type (drug transporting) P-Sp in cationic drug elimination was
further investigated in aiao using the mdfla/ mdrlb gene "knockout" mouse model
(chapter 7) that lacks both mdrla as well as the mdrLb P-gp isoform. These studies
provided further evidence for an important role of mdrl-type P-gp in hepatic as
well as intestinal secretion of organic cations: the excretion of the cationic model
compounds TBuMA, APM and vecuronium were at leastT0o/" reduced in absence
of the mdrl a/\b P-gps.Interestingly the renal clearance of both the typel and the
type2 cations was significantly increased in absence of both mdrla and mdrLb P-
gp. Vecuronium renal clearance was even about S-fold increased. Interestingly
(chnpter 7 ) in mdrla /1b1-1-1mice the clearance of TBuMA as well as that of APM
shifted to the renal secretory route that resulted in an increased renal clearance
that compensated for the reduced hepatic and intestinal clearance. The
mechanism causing the increased renal clearance of typeL cationic compounds in
the mdrla/lb P-gp deficient mice remains to be clarified. Complete absence of
drug transporting (mdr1-type) P-gp could result in secondary changes that
influence organic cation elimination from the body.
Therefore, we more definitely established the direct involvement of mdrl-type P-
gp in organic cation transport by using epithelial cells that were transfected with
various cDNA's encoding mdrl-type P-gps (chapter 8). Apical directed transport
of all tested compounds in polarized grown epithelial LLC-PK1 cells was
significantly increased when P-gp was expressed. This indicates that P-gp can
mediate the transport of aliphatic as well as of more bulky cationic compounds in
such a cell system. These observations also support the in aiuo data indicating that
mdrl-type P-gps are involved in the elimination form the body of a wide variety
of amphiphilic drugs.
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